US FDA consults on medical device user fee programme
This article was originally published in RAJ Devices
The US Food and Drug Administration is planning to hold a public meeting on 14 September to gather input on how its next medical device user fee programme should be framed1. The current legislative authority for the programme ends in September 2012 and new legislation will be required for the FDA to be able to continue collecting user fees from medical device companies.
You may also be interested in...
Italian medicines agency chief Nicola Magrini recounts the problems AIFA faced and the lessons it learned through its work at the height of the coronavirus outbreak in Italy.
EU guidance offers high-level recommendations on the steps that clinical trial sponsors should take to assess the impact of COVID-19 on the quality and reliability of data being generated in ongoing studies. Early scientific advice is recommended if changes must be made to existing protocols or data analysis plans.
The COVID-19 pandemic has given a fresh impetus to the ongoing EU project on remote decentralized trials with more appetite for innovative approaches.